News | January 02, 2025
Akums commissions new manufacturing facility for Lyophilized and Sterile dosage
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Subscribe To Our Newsletter & Stay Updated
